The Role of Integrin-Linked Kinase (ILK) in Acute Myeloid Leukaemia

Acute myeloid leukaemia is an aggressive blood cancer. Unfortunately, around 75% of AML patients who receive intensive chemotherapy experience a relapse within 2 years of remission. Integrin-linked kinase (ILK) is overexpressed in many human cancers. However, its function in AML is yet to be determined. In this study, I demonstrated that ILK inhibition decreased AML cell proliferation and survival. In addition, I show a novel role for ILK in promoting AML cell survival. Moreover, ILK inhibition sensitises AML cells to other targeted therapies. Overall, these findings suggest that blocking ILK could eliminate AML cells and overcome resistance to therapy.